Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at marketsectormovers.com, will continue to monitor these healthtech companies to see if the momentum continues. MarketSectorMovers.com is also looking into these tickers DAWN, COGT, RMD, BSX, RACE, RTX and more..
Recent XNCR Stock Price: $35.14
Summary: Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.
Michael King analyst at EF Hutton reiterates coverage on Xencor (XNCR) stock in the energy sector with a Buy rating and has set XNCR's stock price target at $ 42.
TipRanks.com reports that Xencor currently has 12 analysts offering 12-month price targets on XNCR and the consensus is a Strong Buy rating with an average stock price target of $44.90. The most recent XNCR stock price we have is $35.14 and we are not making any XNCR forecasts at this time.
In addition, TradingView issued a Strong Buy rating for XNCR over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on XNCR. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on XNCR, please click here >>
Cabaletta Bio, CABA
Recent CABA Stock Price: $12.19
Summary: Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States.
Michael Ulz analyst at Morgan Stanley reiterates coverage on Cabaletta Bio (CABA) stock in the energy sector with a Buy rating and has set CABA's stock price target at $ 16.
TipRanks.com reports that Cabaletta Bio currently has 5 analysts offering 12-month price targets on CABA and the consensus is a Strong Buy rating with an average stock price target of $12.60. The most recent CABA stock price we have is $12.19 and we are not making any CABA forecasts at this time.
In addition, TradingView issued a Buy rating for CABA over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on CABA. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on CABA, please click here >>
4D Molecular Therapeutics, FDMT
Recent FDMT Stock Price: $23.05
Summary: 4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California.
Kostas Biliouris analyst at BMO Capital reiterates coverage on 4D Molecular Therapeutics (FDMT) stock in the energy sector with a Buy rating and has set FDMT's stock price target at $ 50.
TipRanks.com reports that 4D Molecular Therapeutics currently has 6 analysts offering 12-month price targets on FDMT and the consensus is a Strong Buy rating with an average stock price target of $40.67. The most recent FDMT stock price we have is $23.05 and we are not making any FDMT forecasts at this time.
In addition, TradingView issued a Strong Buy rating for FDMT over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on FDMT. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on FDMT, please click here >>
Denali Therapeutics, DNLI
Recent DNLI Stock Price: $32.67
Summary: Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program partnered with Biogen to address Parkinson's disease, an eukaryotic translation initiation factor 2B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia (FTD), the ETV:IDS program, which utilizes the company's enzyme transport vehicle technology, and is designed to restore iduronate 2-sulfatase and reduce glycosaminoglycans, in patients with mucopolysaccharidosis II, and two separate receptor interacting serine/threonine protein kinase 1 inhibitor programs, both partnered with Sanofi. It also has a collaboration and option agreement with Takeda Pharmaceutical Co. Ltd. Takeda has exercised its option to jointly develop and commercialize DNL593 with the company.
Marc Goodman analyst at SVB Securities reiterates coverage on Denali Therapeutics (DNLI) stock in the energy sector with a Buy rating and has set DNLI's stock price target at $ 50.
TipRanks.com reports that Denali Therapeutics currently has 10 analysts offering 12-month price targets on DNLI and the consensus is a Strong Buy rating with an average stock price target of $60.67. The most recent DNLI stock price we have is $32.67 and we are not making any DNLI forecasts at this time.
In addition, TradingView issued a Strong Buy rating for DNLI over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on DNLI. marketsectormovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on DNLI, please click here >>
The editors at marketsectormovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
MarketSectorMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to MarketSectorMovers.com.
==============================================================================
